Isabelle Murray
About Isabelle Murray
Isabelle Murray is a Senior Director of Regulatory Affairs at Arcus Biosciences, where she has worked since 2023. She has extensive experience in regulatory roles, including positions at Eli Lilly and Company, Cascadian Therapeutics, and Omeros Corporation.
Current Role at Arcus Biosciences
Isabelle Murray serves as the Senior Director of Regulatory Affairs at Arcus Biosciences. She has held this position since 2023, contributing to the company's regulatory strategies and compliance efforts. Her role involves overseeing regulatory submissions and ensuring adherence to industry standards.
Previous Experience at Arcus Biosciences
Prior to her current position, Isabelle held the role of Director of Regulatory Affairs at Arcus Biosciences from 2021 to 2023. In this capacity, she managed regulatory processes and collaborated with cross-functional teams to support product development and approval.
Professional Background in Regulatory Affairs
Isabelle has extensive experience in regulatory affairs, having worked in various capacities across multiple organizations. She was a Senior Manager of Regulatory Affairs at Omeros Corporation from 2019 to 2020 and served as Associate Director of Regulatory Affairs at the same company from 2020 to 2021. Her previous roles also include positions at Cascadian Therapeutics, Inc. and Seattle Genetics.
Educational Background in Microbiology and Physiology
Isabelle Murray earned a Bachelor of Science in Microbiology from Université Laval, completing her studies from 1992 to 1995. She furthered her education with a Master of Science in Physiology-Endocrinology at the same institution, which she completed from 1995 to 1998. This educational foundation supports her expertise in the regulatory field.
Career at Eli Lilly and Company
Isabelle began her career at Eli Lilly and Company, where she worked for seven years as a Medical Writer from 2003 to 2010. She then transitioned to a role as a Regulatory Scientist at the company, serving from 2010 to 2015. Her tenure at Eli Lilly provided her with a strong foundation in regulatory processes.